Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …

Background Treatments for small-cell lung cancer (SCLC) after failure of platinum-based
chemotherapy are limited. We assessed safety and activity of nivolumab and nivolumab plus …

Small cell neuroendocrine cancers (SCNCs) are recalcitrant cancers arising from diverse
primary sites that lack effective treatments. Using chemical genetic screens, we identified …

Purpose: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to
first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab …

Introduction EGFR-mutant lung cancers are clinically and genomically heterogeneous with
concurrent RB transcriptional corepressor 1 (RB1)/tumor protein p53 (TP53) alterations …

Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …

R. Garcia-Carbonero a H. Sorbye b E. Baudin c E. Raymond d B. Wiedenmann e B. Niederle
f E. Sedlackova g C. Toumpanakis h M. Anlauf i JB Cwikla j M. Caplin k D. O'Toole l A …

Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately
14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed …